Skip to main content

Pheochromocytoma: Unmasking the Chameleon

  • Chapter
  • First Online:

Part of the book series: Contemporary Endocrinology ((COE))

Abstract

Pheochromocytomas and extraadrenal paragangliomas are functional tumors of the neuroendocrine system. They can secrete excessive amounts of catecholamines and although signs and symptoms may vary, generally they present as hypertension accompanied by sympathetic signs and symptoms.

Plasma or urine metanephrines are reliable biochemical tests that are sensitive to detect patients with biochemically active tumors. CT-scan and MRI are anatomic imaging tests that remain vital for accurate pre-operative assessment. Functional imaging can be diagnostic and therapeutic; it enables detection of tumor extent and assesses possible response to therapy.

Focus on genetic studies for familial predisposition for early detection is now at the forefront of research. Identification of SDHB mutations warrants aggressive treatment because of the propensity of these tumors for metastases with poor prognosis.

Surgery remains the cornerstone of treatment with potential cure for benign tumors and palliative management. Long-term follow-up is necessary to detect recurrences and metastases. Malignancy still holds poor prognosis as therapeutic options remain limited. Radiopharmaceutical and chemotherapy remains promising but no major breakthroughs have been achieved. Palliative care and lesion-based treatment remains the standard.

Keywords

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Delellis RA, Lloyd RV, Heitz PU, Eng C. Pathology and genetics of tumors of the endocrine organs. Lyon: IARC Press; 2004.

    Google Scholar 

  2. Tischler AS. Pheochromocytoma and extra-adrenal paraganglioma: updates. Arch Pathol Lab Med. 2008;132(8):1272–84.

    PubMed  Google Scholar 

  3. Manger WM, Gifford RW. Pheochromocytoma. J Clin Hypertens (Greenwich). 2002;4(1):62–72.

    Article  Google Scholar 

  4. Bravo EL, Tagle R. Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev. 2003;24(4):539–53.

    Article  PubMed  CAS  Google Scholar 

  5. Beard CM, Sheps SG, Kurland LT, Carney JA, Lie JT. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc. 1983;58(12):802–4.

    PubMed  CAS  Google Scholar 

  6. Ilias I, Pacak K. A clinical overview of pheochromocytomas/paragangliomas and carcinoid tumors. Nucl Med Biol. 2008;35 Suppl 1:S27–34.

    Article  PubMed  CAS  Google Scholar 

  7. Bin X, Qing Y, Linhui W, Li G, Yinghao S. Adrenal incidentalomas: experience from a retrospective study in a Chinese population. Urol Oncol. 2011;29(3):270–4.

    Article  PubMed  Google Scholar 

  8. Gimenez-Roqueplo AP, Lehnert H, Mannelli M, et al. Phaeochromocytoma, new genes and screening strategies. Clin Endocrinol (Oxf). 2006;65(6):699–705.

    Article  CAS  Google Scholar 

  9. Amar L, Bertherat J, Baudin E, et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol. 2005;23(34):8812–8.

    Article  PubMed  CAS  Google Scholar 

  10. Gutmann DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA. 1997;278(1):51–7.

    Article  PubMed  CAS  Google Scholar 

  11. Machens A, Brauckhoff M, Gimm O, Dralle H. Risk-oriented approach to hereditary adrenal pheochromocytoma. Ann N Y Acad Sci. 2006;1073:417–28.

    Article  PubMed  Google Scholar 

  12. Walther MM, Herring J, Enquist E, Keiser HR, Linehan WM. von Recklinghausen’s disease and pheochromocytomas. J Urol. 1999;162(5):1582–6.

    Article  PubMed  CAS  Google Scholar 

  13. Bausch B, Borozdin W, Neumann HP. Clinical and genetic characteristics of patients with neurofibromatosis type 1 and pheochromocytoma. N Engl J Med. 2006;354(25):2729–31.

    Article  PubMed  CAS  Google Scholar 

  14. Glasker S, Neumann HPH, Koch CA, Vortmeyer AO. Von Hippel Lindau syndrome. Chapter 35 (Section editor: George P. Chrousos) in: Leslie De Groot, editor, online http://www.endotext.org/adrenal/adrenal35/adrenalframe35.htm.

    Article  PubMed  CAS  Google Scholar 

  15. Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease. Lancet. 2003;361(9374):2059–67.

    Article  PubMed  CAS  Google Scholar 

  16. Walther MM, Reiter R, Keiser HR, et al. Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. J Urol. 1999;162(3 Pt 1):659–64.

    Article  PubMed  CAS  Google Scholar 

  17. Eisenhofer G, Walther MM, Huynh TT, et al. Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab. 2001;86(5):1999–2008.

    Article  PubMed  CAS  Google Scholar 

  18. Koch CA, Mauro D, Walther MM, et al. Pheochromocytoma in von Hippel-Lindau disease: distinct histopathologic phenotype compared to pheochromocytoma in multiple endocrine neoplasia type 2. Endocr Pathol. 2002;13(1):17–27.

    Article  PubMed  CAS  Google Scholar 

  19. Recasens M, Oriola J, Fernandez-Real JM, et al. Asymptomatic bilateral adrenal pheochromocytoma in a patient with a germline V804M mutation in the RET proto-oncogene. Clin Endocrinol (Oxf). 2007;67(1):29–33.

    Article  CAS  Google Scholar 

  20. Gimm O, Koch CA, Januszewicz A, Opocher G, Neumann HP. The genetic basis of pheochromocytoma. Front Horm Res. 2004;31:45–60.

    Article  PubMed  CAS  Google Scholar 

  21. Bryant J, Farmer J, Kessler LJ, Townsend RR, Nathanson KL. Pheochromocytoma: the expanding genetic differential diagnosis. J Natl Cancer Inst. 2003;95(16):1196–204.

    Article  PubMed  CAS  Google Scholar 

  22. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86(12):5658–71.

    Article  PubMed  CAS  Google Scholar 

  23. Machens A, Niccoli-Sire P, Hoegel J, et al. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med. 2003;349(16):1517–25.

    Article  PubMed  CAS  Google Scholar 

  24. Gottlieb E, Tomlinson IP. Mitochondrial tumour suppressors: a genetic and biochemical update. Nat Rev Cancer. 2005;5(11):857–66.

    Article  PubMed  CAS  Google Scholar 

  25. Lee S, Nakamura E, Yang H, et al. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell. 2005;8(2):155–67.

    Article  PubMed  CAS  Google Scholar 

  26. Neumann HP, Pawlu C, Peczkowska M, et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA. 2004;292(8):943–51.

    Article  PubMed  CAS  Google Scholar 

  27. Benn DE, Gimenez-Roqueplo AP, Reilly JR, et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab. 2006;91(3):827–36.

    Article  PubMed  CAS  Google Scholar 

  28. Young Jr WF, Abboud AL. Editorial: paraganglioma–all in the family. J Clin Endocrinol Metab. 2006;91(3):790–2.

    Article  PubMed  CAS  Google Scholar 

  29. Baysal BE, Willett-Brozick JE, Lawrence EC, et al. Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet. 2002;39(3):178–83.

    Article  PubMed  CAS  Google Scholar 

  30. Schiavi F, Boedeker CC, Bausch B, et al. Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA. 2005;294(16):2057–63.

    Article  PubMed  CAS  Google Scholar 

  31. Timmers HJ, Kozupa A, Eisenhofer G, et al. Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. J Clin Endocrinol Metab. 2007; 92(3):779–86.

    Article  PubMed  CAS  Google Scholar 

  32. Gimenez-Roqueplo AP, Favier J, Rustin P, et al. Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma. J Clin Endocrinol Metab. 2002;87(10):4771–4.

    Article  PubMed  CAS  Google Scholar 

  33. Gimenez-Roqueplo AP, Favier J, Rustin P, et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res. 2003;63(17):5615–21.

    PubMed  CAS  Google Scholar 

  34. Amar L, Baudin E, Burnichon N, et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab. 2007;92(10):3822–8.

    Article  PubMed  CAS  Google Scholar 

  35. Majumdar S, Friedrich CA, Koch CA, Megason GC, Fratkin JD, Moll GW. Compound heterozygous mutation with a novel splice donor region DN sequence variant in the succinate dehydrogenase subunit B gene in malignant paraganglioma. Pediatr Blood Cancer. 2010;54:473–75.

    Article  PubMed  CAS  Google Scholar 

  36. Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002;346(19):1459–66.

    Article  PubMed  CAS  Google Scholar 

  37. Neumann HP, Eng C. The approach to the patient with paraganglioma. J Clin Endocrinol Metab. 2009;94(8):2677–83.

    Article  PubMed  CAS  Google Scholar 

  38. Erlic Z, Neumann HP. When should genetic testing be obtained in a patient with phaeochromocytoma or paraganglioma? Clin Endocrinol (Oxf). 2009;70(3):354–7.

    Article  Google Scholar 

  39. Eisenhofer G, Huynh TT, Hiroi M, Pacak K. Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma. Rev Endocr Metab Disord. 2001;2(3):297–311.

    Article  PubMed  CAS  Google Scholar 

  40. Edwards RH. The transport of neurotransmitters into synaptic vesicles. Curr Opin Neurobiol. 1992;2(5):586–94.

    Article  PubMed  CAS  Google Scholar 

  41. Cleary S, Brouwers FM, Eisenhofer G, et al. Expression of the noradrenaline transporter and phenylethanolamine N-methyltransferase in normal human adrenal gland and phaeochromocytoma. Cell Tissue Res. 2005;322(3):443–53.

    Article  PubMed  CAS  Google Scholar 

  42. Eisenhofer G, Rundquist B, Aneman A, et al. Regional release and removal of catecholamines and extraneuronal metabolism to metanephrines. J Clin Endocrinol Metab. 1995;80(10): 3009–17.

    Article  PubMed  CAS  Google Scholar 

  43. Kantorovich V, Eisenhofer G, Pacak K. Pheochromocytoma: an endocrine stress mimicking disorder. Ann N Y Acad Sci. 2008;1148:462–8.

    Article  PubMed  Google Scholar 

  44. Goldstein DS, Eisenhofer G, Stull R, Folio CJ, Keiser HR, Kopin IJ. Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans. J Clin Invest. 1988;81(1):213–20.

    Article  PubMed  CAS  Google Scholar 

  45. Eisenhofer G, Keiser H, Friberg P, et al. Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors. J Clin Endocrinol Metab. 1998;83(6):2175–85.

    Article  PubMed  CAS  Google Scholar 

  46. Goldstein DS, Eisenhofer G, Kopin IJ. Sources and significance of plasma levels of catechols and their metabolites in humans. J Pharmacol Exp Ther. 2003;305(3):800–11.

    Article  PubMed  CAS  Google Scholar 

  47. Manger WM. The protean manifestations of pheochromocytoma. Horm Metab Res. 2009;41 (9):658–63.

    Article  PubMed  CAS  Google Scholar 

  48. Manger WM. Editorial: in search of pheochromocytomas. J Clin Endocrinol Metab. 2003;88(9):4080–2.

    Article  PubMed  CAS  Google Scholar 

  49. Eisenhofer G, Kopin IJ, Goldstein DS. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev. 2004;56(3):331–49.

    Article  PubMed  CAS  Google Scholar 

  50. Ito Y, Fujimoto Y, Obara T. The role of epinephrine, norepinephrine, and dopamine in blood pressure disturbances in patients with pheochromocytoma. World J Surg. 1992;16(4):759–63; ­discussion 763–4.

    Google Scholar 

  51. Bravo EL, Tarazi RC, Fouad FM, Textor SC, Gifford Jr RW, Vidt DG. Blood pressure regulation in pheochromocytoma. Hypertension. 1982;4(3 Pt 2):193–9.

    PubMed  CAS  Google Scholar 

  52. Koch CA, Rodbard JS, Brouwers FM, Eisenhofer G, Pacak K. Hypotension in a woman with a metastatic dopamine-secreting carotid body tumor. Endocr Pract. 2003;9(4):310–4.

    Article  PubMed  CAS  Google Scholar 

  53. Tsujimoto G, Manger WM, Hoffman BB. Desensitization of beta-adrenergic receptors by pheochromocytoma. Endocrinology. 1984;114(4):1272–8.

    Article  PubMed  CAS  Google Scholar 

  54. Manger WM. An overview of pheochromocytoma: history, current concepts, vagaries, and diagnostic challenges. Ann N Y Acad Sci. 2006;1073:1–20.

    Article  PubMed  CAS  Google Scholar 

  55. Sode J, Getzen LC, Osborne DP. Cardiac arrhythmias and cardiomyopathy associated with pheochromocytomas. Report of three cases. Am J Surg. 1967;114(6):927–31.

    Article  PubMed  CAS  Google Scholar 

  56. Musuraca G, Imperadore F, Terraneo C, et al. Pheochromocytoma mimicking a non-ST elevation acute myocardial infarction. Cardiol J. 2009;16(4):355–7.

    PubMed  Google Scholar 

  57. Menke-van der Houven van Oordt CW, Twickler TB, van Asperdt FG, Ackermans P, Timmers HJ, Hermus AR. Pheochromocytoma mimicking an acute myocardial infarction. Neth Heart J. 2007;15(7–8):248–51.

    Article  PubMed  CAS  Google Scholar 

  58. Attar MN, Moulik PK, Salem GD, Rose EL, Khaleeli AA. Phaeochromocytoma presenting as dilated cardiomyopathy. Int J Clin Pract. 2003;57(6):547–8.

    PubMed  CAS  Google Scholar 

  59. Kelley SR, Goel TK, Smith JM. Pheochromocytoma presenting as acute severe congestive heart failure, dilated cardiomyopathy, and severe mitral valvular regurgitation: a case report and review of the literature. J Surg Educ. 2009;66(2):96–101.

    Article  PubMed  Google Scholar 

  60. Rosenbaum JS, Billingham ME, Ginsburg R, Tsujimoto G, Lurie KG, Hoffman BB. Cardiomyopathy in a rat model of pheochromocytoma. Morphological and functional alterations. Am J Cardiovasc Pathol. 1988;1(3):389–99.

    PubMed  CAS  Google Scholar 

  61. Holaj R, Zelinka T, Wichterle D, et al. Increased carotid intima-media thickness in patients with pheochromocytoma in comparison to essential hypertension. J Hum Hypertens. 2009;23(5):350–8.

    Article  PubMed  CAS  Google Scholar 

  62. Jang SY, Yang DH, Lee SH, et al. Recurrent catecholamine-induced cardiomyopathy in a patient with a pheochromocytoma. Korean Circ J. 2009;39(6):254–7.

    Article  PubMed  Google Scholar 

  63. Wu XM, Chen JJ, Wu CK, Lin LY, Tseng CD. Pheochromocytoma presenting as acute myocarditis with cardiogenic shock in two cases. Intern Med. 2008;47(24):2151–5.

    Article  PubMed  Google Scholar 

  64. Pacak K, Eisenhofer G, Ahlman H, et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab. 2007;3(2):92–102.

    Article  PubMed  Google Scholar 

  65. Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA. 2002;287(11):1427–34.

    Article  PubMed  CAS  Google Scholar 

  66. Grossman A, Pacak K, Sawka A, et al. Biochemical diagnosis and localization of pheochromocytoma: can we reach a consensus? Ann N Y Acad Sci. 2006;1073:332–47.

    Article  PubMed  CAS  Google Scholar 

  67. Eisenhofer G, Goldstein DS, Sullivan P, et al. Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. J Clin Endocrinol Metab. 2005;90(4):2068–75.

    Article  PubMed  CAS  Google Scholar 

  68. Eisenhofer G, Goldstein D, Kopin I. Simultaneous liquid-chromatographic determination of plasma catecholamines and metabolites. Clin Chem. 2009;55(12):2223–4.

    Article  PubMed  CAS  Google Scholar 

  69. Perry CG, Sawka AM, Singh R, Thabane L, Bajnarek J, Young Jr WF. The diagnostic efficacy of urinary fractionated metanephrines measured by tandem mass spectrometry in detection of pheochromocytoma. Clin Endocrinol (Oxf). 2007;66(5):703–8.

    Article  CAS  Google Scholar 

  70. Eisenhofer G, Siegert G, Kotzerke J, Bornstein SR, Pacak K. Current progress and future challenges in the biochemical diagnosis and treatment of pheochromocytomas and paragangliomas. Horm Metab Res. 2008;40(5):329–37.

    Article  PubMed  CAS  Google Scholar 

  71. Peaston RT, Graham KS, Chambers E, van der Molen JC, Ball S. Performance of plasma free metanephrines measured by liquid chromatography-tandem mass spectrometry in the diagnosis of pheochromocytoma. Clin Chim Acta. 2010;411(7–8):546–52.

    Article  PubMed  CAS  Google Scholar 

  72. Eisenhofer G, Lenders JW, Goldstein DS, et al. Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. Clin Chem. 2005;51(4):735–44.

    Article  PubMed  CAS  Google Scholar 

  73. Eisenhofer G, Goldstein DS, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab. 2003;88(6):2656–66.

    Article  PubMed  CAS  Google Scholar 

  74. Lenders JW, Willemsen JJ, Eisenhofer G, et al. Is supine rest necessary before blood sampling for plasma metanephrines? Clin Chem. 2007;53(2):352–4.

    Article  PubMed  CAS  Google Scholar 

  75. de Jong WH, Eisenhofer G, Post WJ, Muskiet FA, de Vries EG, Kema IP. Dietary influences on plasma and urinary metanephrines: implications for diagnosis of catecholamine-producing tumors. J Clin Endocrinol Metab. 2009;94(8):2841–9.

    Article  PubMed  CAS  Google Scholar 

  76. Bravo EL, Tarazi RC, Fouad FM, Vidt DG, Gifford Jr RW. Clonidine-suppression test: a useful aid in the diagnosis of pheochromocytoma. N Engl J Med. 1981;305(11):623–6.

    Article  PubMed  CAS  Google Scholar 

  77. Lenders JW, Pacak K, Huynh TT, et al. Low sensitivity of glucagon provocative testing for diagnosis of pheochromocytoma. J Clin Endocrinol Metab. 2010;95(1):238–45.

    Article  PubMed  CAS  Google Scholar 

  78. Grossrubatscher E, Dalino P, Vignati F, et al. The role of chromogranin A in the management of patients with phaeochromocytoma. Clin Endocrinol (Oxf). 2006;65(3):287–93.

    Article  CAS  Google Scholar 

  79. Bilek R, Safarik L, Ciprova V, Vlcek P, Lisa L. Chromogranin A, a member of neuroendocrine secretory proteins as a selective marker for laboratory diagnosis of pheochromocytoma. Physiol Res. 2008;57 Suppl 1:S171–9.

    PubMed  CAS  Google Scholar 

  80. Miehle K, Kratzsch J, Lenders JW, Kluge R, Paschke R, Koch CA. Adrenal incidentaloma diagnosed as pheochromocytoma by plasma chromogranin A and plasma metanephrines. J Endocrinol Invest. 2005;28(11):1040–2.

    PubMed  CAS  Google Scholar 

  81. Giovanella L, Squin N, Ghelfo A, Ceriani L. Chromogranin A immunoradiometric assay in diagnosis of pheochromocytoma: comparison with plasma metanephrines and 123I-MIBG scan. Q J Nucl Med Mol Imaging. 2006;50(4):344–7.

    PubMed  CAS  Google Scholar 

  82. d’Herbomez M, Forzy G, Bauters C, et al. An analysis of the biochemical diagnosis of 66 pheochromocytomas. Eur J Endocrinol. 2007;156(5):569–75.

    Article  PubMed  CAS  Google Scholar 

  83. Rao F, Keiser HR, O’Connor DT. Malignant pheochromocytoma. Chromaffin granule transmitters and response to treatment. Hypertension. 2000;36(6):1045–52.

    Article  PubMed  CAS  Google Scholar 

  84. La Batide-Alanore A, Chatellier G, Plouin PF. Diabetes as a marker of pheochromocytoma in hypertensive patients. J Hypertens. 2003;21(9):1703–7.

    Article  PubMed  Google Scholar 

  85. East HE, Subauste JS, Gandhi A, Koch CA. 10 things you need to know about secondary causes of diabetes mellitus. J Miss State Med Assoc. 2012;in press.

    Article  PubMed  Google Scholar 

  86. Winocour PH, Masud T, Clark F, Cooper BG, Laker MF, Alberti KG. Lipid and lipoprotein metabolism in familial combined hyperlipidaemia during treatment of sporadic phaeochromocytoma: a case study. Postgrad Med J. 1992;68(799):371–5.

    Article  PubMed  CAS  Google Scholar 

  87. Zapanti E, Ilias I. Pheochromocytoma: physiopathologic implications and diagnostic evaluation. Ann N Y Acad Sci. 2006;1088:346–60.

    Article  PubMed  CAS  Google Scholar 

  88. Lockhart ME, Smith JK, Kenney PJ. Imaging of adrenal masses. Eur J Radiol. 2002;41(2):95–112.

    Article  PubMed  Google Scholar 

  89. Heinz-Peer G, Memarsadeghi M, Niederle B. Imaging of adrenal masses. Curr Opin Urol. 2007;17(1):32–8.

    Article  PubMed  Google Scholar 

  90. Korobkin M, Brodeur FJ, Yutzy GG, et al. Differentiation of adrenal adenomas from nonadenomas using CT attenuation values. AJR Am J Roentgenol. 1996;166(3):531–6.

    PubMed  CAS  Google Scholar 

  91. Hamrahian AH, Ioachimescu AG, Remer EM, et al. Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience. J Clin Endocrinol Metab. 2005;90(2):871–7.

    Article  PubMed  CAS  Google Scholar 

  92. Mayo-Smith WW, Boland GW, Noto RB, Lee M. From the RSNA refresher courses—State-of-the-art adrenal imaging. Radiographics. 2001;21(4):995–1012.

    PubMed  CAS  Google Scholar 

  93. Jacques AE, Sahdev A, Sandrasagara M, et al. Adrenal phaeochromocytoma: correlation of MRI appearances with histology and function. Eur Radiol. 2008;18(12):2885–92.

    Article  PubMed  Google Scholar 

  94. Sahdev A, Sohaib A, Monson JP, Grossman AB, Chew SL, Reznek RH. CT and MR imaging of unusual locations of extra-adrenal paragangliomas (pheochromocytomas). Eur Radiol. 2005;15(1):85–92.

    Article  PubMed  Google Scholar 

  95. Whalen RK, Althausen AF, Daniels GH. Extra-adrenal pheochromocytoma. J Urol. 1992; 147(1):1–10.

    PubMed  CAS  Google Scholar 

  96. Shulkin BL, Ilias I, Sisson JC, Pacak K. Current trends in functional imaging of pheochromocytomas and paragangliomas. Ann N Y Acad Sci. 2006;1073:374–82.

    Article  PubMed  Google Scholar 

  97. Ilias I, Shulkin B, Pacak K. New functional imaging modalities for chromaffin tumors, neuroblastomas and ganglioneuromas. Trends Endocrinol Metab. 2005;16(2):66–72.

    Article  PubMed  CAS  Google Scholar 

  98. Brink I, Hoegerle S, Klisch J, Bley TA. Imaging of pheochromocytoma and paraganglioma. Fam Cancer. 2005;4(1):61–8.

    Article  PubMed  CAS  Google Scholar 

  99. Wiseman GA, Pacak K, O’Dorisio MS, et al. Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial. J Nucl Med. 2009;50(9): 1448–54.

    Article  PubMed  CAS  Google Scholar 

  100. Bhatia KS, Ismail MM, Sahdev A, et al. 123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation. Clin Endocrinol (Oxf). 2008;69(2):181–8.

    Article  Google Scholar 

  101. Taieb D, Sebag F, Hubbard JG, Mundler O, Henry JF, Conte-Devolx B. Does iodine-131 meta-iodobenzylguanidine (MIBG) scintigraphy have an impact on the management of sporadic and familial phaeochromocytoma? Clin Endocrinol (Oxf). 2004;61(1):102–8.

    Article  CAS  Google Scholar 

  102. Lonsdale MN, Beyer T. Dual-modality PET/CT instrumentation-today and tomorrow. Eur J Radiol. 2010;73(3):452–60.

    Article  PubMed  Google Scholar 

  103. Timmers HJ, Carrasquillo JA, Whatley M, et al. Usefulness of standardized uptake values for distinguishing adrenal glands with pheochromocytoma from normal adrenal glands by use of 6-18F-fluorodopamine PET. J Nucl Med. 2007;48(12):1940–4.

    Article  PubMed  CAS  Google Scholar 

  104. Pacak K, Eisenhofer G, Carrasquillo JA, Chen CC, Li ST, Goldstein DS. 6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension. 2001;38(1):6–8.

    Article  PubMed  CAS  Google Scholar 

  105. Ilias I, Yu J, Carrasquillo JA, et al. Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab. 2003;88(9):4083–7.

    Article  PubMed  CAS  Google Scholar 

  106. Kaji P, Carrasquillo JA, Linehan WM, et al. The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome. Eur J Endocrinol. 2007;156(4):483–7.

    Article  PubMed  CAS  Google Scholar 

  107. Timmers HJ, Eisenhofer G, Carrasquillo JA, et al. Use of 6-[18F]-fluorodopamine positron emission tomography (PET) as first-line investigation for the diagnosis and localization of non-metastatic and metastatic phaeochromocytoma (PHEO). Clin Endocrinol (Oxf). 2009;71(1):11–7.

    Article  Google Scholar 

  108. Havekes B, King K, Lai EW, Romijn JA, Corssmit EP, Pacak K. New imaging approaches to phaeochromocytomas and paragangliomas. Clin Endocrinol (Oxf). 2009;72(2):137–45.

    Article  CAS  Google Scholar 

  109. Timmers HJ, Hadi M, Carrasquillo JA, et al. The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. J Nucl Med. 2007;48(10):1599–606.

    Article  PubMed  CAS  Google Scholar 

  110. Fiebrich HB, Brouwers AH, Kerstens MN, et al. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. J Clin Endocrinol Metab. 2009;94(10):3922–30.

    Article  PubMed  CAS  Google Scholar 

  111. Luster M, Karges W, Zeich K, et al. Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma. Eur J Nucl Med Mol Imaging. 2010;37(3):484–93.

    Article  PubMed  Google Scholar 

  112. Hoegerle S, Altehoefer C, Ghanem N, et al. Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology. 2001;220(2):373–80.

    PubMed  CAS  Google Scholar 

  113. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8(6):519–30.

    Article  PubMed  CAS  Google Scholar 

  114. Belhocine T, Spaepen K, Dusart M, et al. 18FDG PET in oncology: the best and the worst (Review). Int J Oncol. 2006;28(5):1249–61.

    PubMed  Google Scholar 

  115. Timmers HJ, Kozupa A, Chen CC, et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol. 2007;25(16):2262–9.

    Article  PubMed  Google Scholar 

  116. Mundschenk J, Unger N, Schulz S, Hollt V, Steinke R, Lehnert H. Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. J Clin Endocrinol Metab. 2003;88(11):5150–7.

    Article  PubMed  CAS  Google Scholar 

  117. McCarthy KE, Woltering EA, Anthony LB. In situ radiotherapy with 111In-pentetreotide. State of the art and perspectives. Q J Nucl Med. 2000;44(1):88–95.

    PubMed  CAS  Google Scholar 

  118. Ilias I, Chen CC, Carrasquillo JA, et al. Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med. 2008;49(10):1613–9.

    Article  PubMed  Google Scholar 

  119. Koopmans KP, Jager PL, Kema IP, Kerstens MN, Albers F, Dullaart RP. 111In-octreotide is superior to 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas. J Nucl Med. 2008;49(8):1232–7.

    Article  PubMed  Google Scholar 

  120. de Jong M, Breeman WA, Bakker WH, et al. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res. 1998;58(3):437–41.

    PubMed  Google Scholar 

  121. Vanhagen PM, Krenning EP, Reubi JC, et al. Somatostatin analogue scintigraphy in granulomatous diseases. Eur J Nucl Med. 1994;21(6):497–502.

    Article  PubMed  CAS  Google Scholar 

  122. King K, Chen CC, Alexopoulos DK, Whatkey MA, Reynolds JC, Patronas N, et al. Functional imaging of SDHx-related head and neck paragangliomas: Comparison of 18F-fluorodihydroxyphenylalanine, 18Ffluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy. J Clin Endocrinol Metab. 2011;96(9):2779–85.

    Article  PubMed  CAS  Google Scholar 

  123. Zelinka T, Timmers HJ, Kozupa A, et al. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations. Endocr Relat Cancer. 2008;15(1):311–23.

    Article  PubMed  Google Scholar 

  124. Pacak K. Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab. 2007;92(11):4069–79.

    Article  PubMed  CAS  Google Scholar 

  125. Sibal L, Jovanovic A, Agarwal SC, et al. Phaeochromocytomas presenting as acute crises after beta blockade therapy. Clin Endocrinol (Oxf). 2006;65(2):186–90.

    Article  CAS  Google Scholar 

  126. Bravo EL. Pheochromocytoma. Cardiol Rev. 2002;10(1):44–50.

    Article  PubMed  Google Scholar 

  127. Steinsapir J, Carr AA, Prisant LM, Bransome Jr ED. Metyrosine and pheochromocytoma. Arch Intern Med. 1997;157(8):901–6.

    Article  PubMed  CAS  Google Scholar 

  128. Perry RR, Keiser HR, Norton JA, et al. Surgical management of pheochromocytoma with the use of metyrosine. Ann Surg. 1990;212(5):621–8.

    Article  PubMed  CAS  Google Scholar 

  129. van der Horst-Schrivers AN, Kerstens MN, Wolffenbuttel BH. Preoperative pharmacological management of phaeochromocytoma. Neth J Med. 2006;64(8):290–5.

    PubMed  Google Scholar 

  130. Mellon MJ, Sundaram CP. Laparoscopic adrenalectomy for pheochromocytoma versus other surgical indications. JSLS. 2008;12(4):380–4.

    PubMed  Google Scholar 

  131. Humphrey R, Gray D, Pautler S, Davies W. Laparoscopic compared with open adrenalectomy for resection of pheochromocytoma: a review of 47 cases. Can J Surg. 2008;51(4):276–80.

    PubMed  Google Scholar 

  132. Meyer-Rochow GY, Soon PS, Delbridge LW, et al. Outcomes of minimally invasive surgery for phaeochromocytoma. ANZ J Surg. 2009;79(5):367–70.

    Article  PubMed  Google Scholar 

  133. Ippolito G, Palazzo FF, Sebag F, Thakur A, Cherenko M, Henry JF. Safety of laparoscopic adrenalectomy in patients with large pheochromocytomas: a single institution review. World J Surg. 2008;32(5):840–44; discussion 845–46.

    Google Scholar 

  134. Jaroszewski DE, Tessier DJ, Schlinkert RT, et al. Laparoscopic adrenalectomy for pheochromocytoma. Mayo Clin Proc. 2003;78(12):1501–4.

    Article  PubMed  Google Scholar 

  135. Kasahara T, Nishiyama T, Takahashi K. Laparoscopic adrenalectomy for pheochromocytoma: evaluation of experience and strategy at a single institute. BJU Int. 2009;103(2):218–22.

    Article  PubMed  Google Scholar 

  136. Dimas S, Roukounakis N, Kafetzis I, et al. Feasibility of laparoscopic adrenalectomy for large pheochromocytomas. JSLS. 2007;11(1):30–3.

    PubMed  CAS  Google Scholar 

  137. Shen WT, Sturgeon C, Clark OH, Duh QY, Kebebew E. Should pheochromocytoma size influence surgical approach? A comparison of 90 malignant and 60 benign pheochromocytomas. Surgery. 2004;136(6):1129–37.

    Article  PubMed  Google Scholar 

  138. Singer J, Koch CA, Kassahun W, Lamesch P, Eisenhofer G, Kluge R, et al. A patient with a large recurrent pheochromocytoma demonstrating the pitfalls of diagnosis. Nat Rev Endocrinol. 2011;7(12):749–55.

    Google Scholar 

  139. Castilho LN, Simoes FA, Santos AM, Rodrigues TM, dos Santos CA Jr. Pheochromocytoma: a long-term follow-up of 24 patients undergoing laparoscopic adrenalectomy. Int Braz J Urol. 2009;35(1):24–31; discussion 32–5.

    Google Scholar 

  140. Petri BJ, van Eijck CH, de Herder WW, Wagner A, de Krijger RR. Phaeochromocytomas and sympathetic paragangliomas. Br J Surg. 2009;96(12):1381–92.

    Article  PubMed  Google Scholar 

  141. Asari R, Scheuba C, Kaczirek K, Niederle B. Estimated risk of pheochromocytoma recurrence after adrenal-sparing surgery in patients with multiple endocrine neoplasia type 2A. Arch Surg. 2006;141(12):1199–205; discussion 1205.

    Google Scholar 

  142. Tischler AS, Kimura N, McNicol AM. Pathology of pheochromocytoma and extra-adrenal paraganglioma. Ann N Y Acad Sci. 2006;1073:557–70.

    Article  PubMed  Google Scholar 

  143. Kimura N, Watanabe T, Noshiro T, Shizawa S, Miura Y. Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors. Endocr Pathol Spring. 2005;16(1):23–32.

    Article  Google Scholar 

  144. Reisin E, Huth MM, Nguyen BP, Weed SG, Gonzalez FM. Intravenous fenoldopam versus sodium nitroprusside in patients with severe hypertension. Hypertension. 1990;15(2 Suppl): I59–62.

    Article  PubMed  CAS  Google Scholar 

  145. Friederich JA, Butterworth JFt. Sodium nitroprusside: twenty years and counting. Anesth Analg. 1995;81(1):152–62.

    PubMed  CAS  Google Scholar 

  146. Joris JL, Hamoir EE, Hartstein GM, et al. Hemodynamic changes and catecholamine release during laparoscopic adrenalectomy for pheochromocytoma. Anesth Analg. 1999;88(1):16–21.

    PubMed  CAS  Google Scholar 

  147. James MF, Cronje L. Pheochromocytoma crisis: the use of magnesium sulfate. Anesth Analg. 2004;99(3):680–6; table of contents.

    Google Scholar 

  148. Shupak RC. Difficult anesthetic management during pheochromocytoma surgery. J Clin Anesth. 1999;11(3):247–50.

    Article  PubMed  CAS  Google Scholar 

  149. Augoustides JG, Abrams M, Berkowitz D, Fraker D. Vasopressin for hemodynamic rescue in catecholamine-resistant vasoplegic shock after resection of massive pheochromocytoma. Anesthesiology. 2004;101(4):1022–4.

    Article  PubMed  Google Scholar 

  150. Deutsch E, Tobias JD. Vasopressin to treat hypotension after pheochromocytoma resection in an eleven-year-old boy. J Cardiothorac Vasc Anesth. 2006;20(3):394–6.

    Article  PubMed  Google Scholar 

  151. Akiba M, Kodama T, Ito Y, Obara T, Fujimoto Y. Hypoglycemia induced by excessive rebound secretion of insulin after removal of pheochromocytoma. World J Surg. 1990;14(3):317–24.

    Article  PubMed  CAS  Google Scholar 

  152. Jude EB, Sridhar CB. Prolonged hypoglycaemia following surgical removal of phaeochromocytoma. Postgrad Med J. 2000;76(891):39–40.

    Article  PubMed  CAS  Google Scholar 

  153. Eisenhofer G, Bornstein SR, Brouwers FM, et al. Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer. 2004;11(3):423–36.

    Article  PubMed  CAS  Google Scholar 

  154. Brouwers FM, Eisenhofer G, Tao JJ, et al. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab. 2006;91(11):4505–9.

    Article  PubMed  CAS  Google Scholar 

  155. John H, Ziegler WH, Hauri D, Jaeger P. Pheochromocytomas: can malignant potential be predicted? Urology. 1999;53(4):679–83.

    Article  PubMed  CAS  Google Scholar 

  156. Fitzgerald PA, Goldsby RE, Huberty JP, et al. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Ann N Y Acad Sci. 2006;1073:465–90.

    Article  PubMed  CAS  Google Scholar 

  157. Amar L, Servais A, Gimenez-Roqueplo AP, Zinzindohoue F, Chatellier G, Plouin PF. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab. 2005;90(4):2110–6.

    Article  PubMed  CAS  Google Scholar 

  158. Goldstein RE, O’Neill JA Jr., Holcomb GW, III, et al. Clinical experience over 48 years with pheochromocytoma. Ann Surg. 1999;229(6):755–64; discussion 764–6.

    Google Scholar 

  159. Ilias I, Pacak K. Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab. 2004;89(2):479–91.

    Article  PubMed  CAS  Google Scholar 

  160. Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer. 2007;14(3):569–85.

    Article  PubMed  CAS  Google Scholar 

  161. Brauckhoff M, Gimm O, Dralle H. Preoperative and surgical therapy in sporadic and familial pheochromocytoma. Front Horm Res. 2004;31:121–44.

    Article  PubMed  Google Scholar 

  162. Kebebew E, Duh QY. Benign and malignant pheochromocytoma: diagnosis, treatment, and follow-Up. Surg Oncol Clin N Am. 1998;7(4):765–89.

    PubMed  CAS  Google Scholar 

  163. Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein DS. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med. 2001;134(4):315–29.

    PubMed  CAS  Google Scholar 

  164. Takahashi K, Ashizawa N, Minami T, et al. Malignant pheochromocytoma with multiple hepatic metastases treated by chemotherapy and transcatheter arterial embolization. Intern Med. 1999;38(4):349–54.

    Article  PubMed  CAS  Google Scholar 

  165. Pham TH, Moir C, Thompson GB, et al. Pheochromocytoma and paraganglioma in children: a review of medical and surgical management at a tertiary care center. Pediatrics. 2006; 118(3):1109–17.

    Article  PubMed  Google Scholar 

  166. Walther MM. New therapeutic and surgical approaches for sporadic and hereditary pheochromocytoma. Ann N Y Acad Sci. 2002;970:41–53.

    Article  PubMed  Google Scholar 

  167. Brunt LM, Lairmore TC, Doherty GM, Quasebarth MA, DeBenedetti M, Moley JF. Adrenalectomy for familial pheochromocytoma in the laparoscopic era. Ann Surg. 2002; 235(5):713–20; discussion 720–1.

    Google Scholar 

  168. Barontini M, Levin G, Sanso G. Characteristics of pheochromocytoma in a 4- to 20-year-old population. Ann N Y Acad Sci. 2006;1073:30–7.

    Article  PubMed  Google Scholar 

  169. Ein SH, Pullerits J, Creighton R, Balfe JW. Pediatric pheochromocytoma. A 36-year review. Pediatr Surg Int. 1997;12(8):595–8.

    PubMed  CAS  Google Scholar 

  170. Turner MC, Lieberman E, DeQuattro V. The perioperative management of pheochromocytoma in children. Clin Pediatr (Phila). 1992;31(10):583–9.

    Article  CAS  Google Scholar 

  171. Vargas HI, Kavoussi LR, Bartlett DL, et al. Laparoscopic adrenalectomy: a new standard of care. Urology. 1997;49(5):673–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This research was supported, in part, by the Intramural Research Program of the NIH, NICHD.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Karel Pacak .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Robles, J.F., Mercado-Asis, L.B., Pacak, K. (2013). Pheochromocytoma: Unmasking the Chameleon. In: Koch, C., Chrousos, G. (eds) Endocrine Hypertension. Contemporary Endocrinology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-548-4_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-548-4_7

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60761-547-7

  • Online ISBN: 978-1-60761-548-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics